ライフサイエンスコーパス: hematopoietic cell transplantation

1 life-threatening complication of allogeneic hematopoietic cell transplantation.

2 reduce the risk of relapse after allogeneic hematopoietic cell transplantation.

3 ablation is commonly used in solid organ and hematopoietic cell transplantation.

4 -versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation.

5 ficant obstacle to the success of allogeneic hematopoietic cell transplantation.

6 m of graft-versus-host interaction following hematopoietic cell transplantation.

7 ietic stem cells (HSCs) during an allogeneic hematopoietic cell transplantation.

8 myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation.

9 Interventions: Unrelated donor BM or PB hematopoietic cell transplantation.

10 in human and murine T cells after allogeneic hematopoietic cell transplantation.

11 uction syndrome, an early complication after hematopoietic cell transplantation.

12 major nonrelapse complication of allogeneic hematopoietic cell transplantation.

13 lly validating this model in unrelated donor hematopoietic cell transplantation.

14 blood from unrelated donors may be used for hematopoietic cell transplantation.

15 life-threatening complication of allogeneic hematopoietic cell transplantation.

16 re white; 45% had leukemia; and 34% received hematopoietic cell transplantation.

17 fection before starting anti-CD20 therapy or hematopoietic cell transplantation.

18 e radiation sickness and patients undergoing hematopoietic cell transplantation.

19 relevant to local wound therapy and systemic hematopoietic cell transplantation.

20 of morbidity and mortality after allogeneic hematopoietic cell transplantation.

21 d leukemia in children undergoing allogeneic hematopoietic cell transplantation.

22 No patients were cured without hematopoietic cell transplantation.

23 radicate tumor and to enhance outcomes after hematopoietic cell transplantation.

24 of damaged host tissues following allogeneic hematopoietic cell transplantation.

25 ut still had fatal complications or required hematopoietic cell transplantation.

26 t rejection or chronic GVHD after allogeneic hematopoietic cell transplantation.

27 d be considered as candidates for allogeneic hematopoietic cell transplantation.

28 D) can result in disability after allogeneic hematopoietic cell transplantation.

29 e peripheral blood stem cells for allogeneic hematopoietic cell transplantation.

30 he tumor site in cooperation with allogeneic hematopoietic cell transplantation.

31 afety and efficacy of alternative donors for hematopoietic cell transplantation.

32 ogic diseases who can be cured by allogeneic hematopoietic cell transplantation.

33 mediate a novel immunoregulatory role during hematopoietic cell transplantation.

34 epresenting a primary NK cell response after hematopoietic cell transplantation.

35 undamental obstacle to successful allogeneic hematopoietic cell transplantation.

36 rly intervention and improved survival after hematopoietic cell transplantation.

37 atment of hematologic malignancies and after hematopoietic cell transplantation.

38 iders who care for patients after allogeneic hematopoietic cell transplantation.

39 national Histocompatibility Working Group in Hematopoietic Cell Transplantation.

40 s, with and without censoring for allogeneic hematopoietic cell transplantation.

41 herapy regimens if ineligible for autologous hematopoietic cell transplantation.

42 the most serious complication of allogeneic hematopoietic cell transplantation.

43 three additional courses of chemotherapy or hematopoietic cell transplantation.

44 of morbidity and mortality after allogeneic hematopoietic cell transplantation.

45 th in patients who have undergone allogeneic hematopoietic-cell transplantation.

46 001 in patients who had undergone allogeneic hematopoietic-cell transplantation.

47 VHD) is the major complication of allogeneic hematopoietic cell transplantation, a potentially curati

48 induced hematopoietic syndrome is allogeneic hematopoietic cell transplantation, a therapy unavailabl

49 Autologous hematopoietic cell transplantation (AHCT) consolidation

50 e-cycle melphalan 200 mg/m(2) and autologous hematopoietic cell transplantation (AHCT) followed by le

51 es influence clinical outcomes in autologous hematopoietic cell transplantation (AHCT) for acute myel

52 Allogeneic hematopoietic cell transplantation (allo-HCT) can cure t

53 GVHD) is a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT) characteri

54 Allogeneic hematopoietic cell transplantation (allo-HCT) is a poten

55 Although allogeneic hematopoietic cell transplantation (allo-HCT) is current

56 immune reconstitution (IR) after allogeneic hematopoietic cell transplantation (allo-HCT) is highly

57 Allogeneic hematopoietic cell transplantation (allo-HCT) is increas

58 Allogeneic hematopoietic cell transplantation (allo-HCT) is indicat

59 treatment of acute leukemias with allogeneic hematopoietic cell transplantation (allo-HCT) is limited

60 t-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation (allo-HCT) represents

61 into the intestinal mucosa after allogeneic hematopoietic cell transplantation (allo-HCT) triggers n

62 cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstra

63 In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we descri

64 tic potential of Fn14 blockade on allogeneic hematopoietic cell transplantation (allo-HCT)-induced in

65 life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT).

66 fe-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT).

67 onsiderably limits wider usage of allogeneic hematopoietic cell transplantation (allo-HCT).

68 of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT).

69 which is the main complication of allogeneic hematopoietic cell transplantation (allo-HCT).

70 sus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT).

71 ease (GVHD) limits the success of allogeneic hematopoietic cell transplantation (allo-HCT); therefore

72 e major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relaps

73 ntensive chemotherapy followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-

74 Allogeneic hematopoietic cell transplantation (alloHCT) benefits in

75 solution for patients who require allogeneic hematopoietic cell transplantation (alloHCT) but lack a

76 Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved

77 graft-vs-tumor effects following allogeneic hematopoietic cell transplantation (alloHCT), but retros

78 morbidity and mortality following allogeneic hematopoietic cell transplantation (AlloHCT).

79 in at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT).

80 Hematopoietic cell transplantation, although potentially

81 eady-state and stressful conditions, such as hematopoietic cell transplantation and G-CSF- or inflamm

82 n adoptively transferred in murine models of hematopoietic cell transplantation and in phase 1/2 clin

83 Strategies to enhance the safety of hematopoietic cell transplantation and to improve patien

84 ncies, assessing immune reconstitution after hematopoietic cell transplantation, and characterizing t

85 VHD) is the primary limitation of allogeneic hematopoietic cell transplantation, and once it develops

86 be used as a novel conditioning regimen for hematopoietic cell transplantation, and raise concerns f

87 The results of hematopoietic cell transplantation are analyzed, and rec

88 istocompatibility complex-matched allogeneic hematopoietic cell transplantation as a platform to deve

89 Allogeneic hematopoietic cell transplantation at the time of second

90 ory DLBCL who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had

91 This information may be useful for enhancing hematopoietic cell transplantation, blood cell recovery

92 imen that prepares recipients for allogeneic hematopoietic cell transplantation by targeting lymph no

93 formation in a model that simulates clinical hematopoietic cell transplantation by transplanting MHC-

94 Allogeneic hematopoietic cell transplantation can achieve cures in

95 Although hematopoietic cell transplantation can be curative, addi

96 Hematopoietic cell transplantation can correct hematolog

97 e phenotype of chronic GVHD after allogeneic hematopoietic cell transplantation, characterized by fib

98 Allogeneic hematopoietic cell transplantation combines the power of

99 Whether the hematopoietic cell transplantation comorbidity index (HC

100 the other hand, older recipient age and high hematopoietic cell transplantation-comorbidity index (HC

101 The hematopoietic cell transplantation-comorbidity index (HC

102 ncluding those already incorporated into the hematopoietic cell transplantation-comorbidity index (HC

103 linical trial using low-intensity allogeneic hematopoietic cell transplantation demonstrated that int

104 The success of allogeneic hematopoietic cell transplantation depends heavily on th

105 prime-boost vaccine regimen in three female hematopoietic cell transplantation donors.

106 depletion of donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents

107 an adaptive immune system through allogeneic hematopoietic cell transplantation, enzyme replacement,

108 e is a major cause of death after allogeneic hematopoietic cell transplantation for acute leukemias.

109 ection to improve outcome of unrelated donor hematopoietic cell transplantation for acute myelogenous

110 analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North Ameri

111 w (BM) vs peripheral blood (PB) (N = 551) in hematopoietic cell transplantation for hematologic neopl

112 ic lymphohistiocytosis (HLH), which requires hematopoietic cell transplantation for long-term cure.

113 Results of hematopoietic cell transplantation for radiation-sensiti

114 Hematopoietic Cell Transplantation for Relapsing-Remitti

115 s of the consortium describe the outcomes of hematopoietic cell transplantation for SCID during 2000-

116 t event-free survival (EFS) after allogeneic hematopoietic cell transplantation for sickle cell disea

117 s in a cohort of 2531 patients who underwent hematopoietic cell transplantation from 2010 to 2015 aft

118 Patients who underwent hematopoietic cell transplantation had an increased risk

119 ituted NK cells obtained from patients after hematopoietic cell transplantation had diminished expres

120 Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using pos

121 Hematopoietic cell transplantation has increased the sur

122 Solid organ and allogeneic hematopoietic cell transplantation have become standard

123 versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis,

124 antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culmina

125 depletion regimen (HR, 0.25), and allogeneic hematopoietic cell transplantation (HCT) after CAR T-cel

126 and 100 cGy total body irradiation prior to hematopoietic cell transplantation (HCT) and a 45-day co

127 Hematopoietic cell transplantation (HCT) and prolonged c

128 tranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are limited by

129 ighlights long-term and late consequences of hematopoietic cell transplantation (HCT) as well as stra

130 Post hematopoietic cell transplantation (HCT) autoimmune cyto

131 Allogeneic hematopoietic cell transplantation (HCT) benefits childr

132 ome (MDS) (n = 371) who underwent allogeneic hematopoietic cell transplantation (HCT) between 1995 an

133 Allogeneic hematopoietic cell transplantation (HCT) can cure bone m

134 Allogeneic hematopoietic cell transplantation (HCT) can potentially

135 a 23% improvement in day +100 survival after hematopoietic cell transplantation (HCT) compared with h

136 Viral reactivations (VRs) after hematopoietic cell transplantation (HCT) contribute to s

137 er insight into humoral viral immunity after hematopoietic cell transplantation (HCT) could have pote

138 ta from genome-wide scans of 1298 allogeneic hematopoietic cell transplantation (HCT) donors and reci

139 ematologic malignancies and those undergoing hematopoietic cell transplantation (HCT) face a complex

140 ary immunodeficiencies undergoing allogeneic hematopoietic cell transplantation (HCT) for difficult-t

141 Historically, alternative donor hematopoietic cell transplantation (HCT) for Fanconi ane

142 ite improvements, mortality after allogeneic hematopoietic cell transplantation (HCT) for nonmalignan

143 In this review we discuss recent outcomes of hematopoietic cell transplantation (HCT) for patients wi

144 cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of

145 We analyzed patients treated with allogeneic hematopoietic cell transplantation (HCT) from 2010 to 20

146 Allogeneic hematopoietic cell transplantation (HCT) from human leuk

147 st disease (GVHD) is higher after allogeneic hematopoietic cell transplantation (HCT) from unrelated

148 Hematopoietic cell transplantation (HCT) has been consid

149 Although hematopoietic cell transplantation (HCT) has been perfor

150 Hematopoietic cell transplantation (HCT) has now been sh

151 one-third of patients with an indication for hematopoietic cell transplantation (HCT) have an HLA-mat

152 GVHD) in several animal models and following hematopoietic cell transplantation (HCT) in clinical tri

153 ltivariate Cox model for OS using allogeneic hematopoietic cell transplantation (HCT) in first comple

154 ntensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients wit

155 studies on patient outcome after allogeneic hematopoietic cell transplantation (HCT) in patients wit

156 nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) in the pediatri

157 intensity treatments and complications after hematopoietic cell transplantation (HCT) injure normal t

158 Hematopoietic cell transplantation (HCT) is a critical t

159 ysosomal storage disorders (LSDs), for which hematopoietic cell transplantation (HCT) is applied to r

160 residual disease (MRD) before myeloablative hematopoietic cell transplantation (HCT) is associated w

161 no acid (AA) polymorphism for the outcome of hematopoietic cell transplantation (HCT) is controversia

162 Hematopoietic cell transplantation (HCT) is curative for

163 rimary cytomegalovirus (CMV) infection after hematopoietic cell transplantation (HCT) is poorly under

164 Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantl

165 ntial component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditio

166 Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading

167 Allogeneic hematopoietic cell transplantation (HCT) is the most eff

168 Presently, allogeneic hematopoietic cell transplantation (HCT) is the only cur

169 gnificant morbidity and early mortality, and hematopoietic cell transplantation (HCT) is the only wid

170 Hematopoietic cell transplantation (HCT) is the primary

171 The success of allogeneic hematopoietic cell transplantation (HCT) is typically as

172 optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown.

173 geneic (allo-allo) or autologous (auto-allo) hematopoietic cell transplantation (HCT) is usually perf

174 y multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients wit

175 C) transfusion practices and their impact on hematopoietic cell transplantation (HCT) outcomes are po

176 n between iron overload and adult allogeneic hematopoietic cell transplantation (HCT) outcomes.

177 VHD) remains a major challenge in allogeneic hematopoietic cell transplantation (HCT) owing to limite

178 may substitute for total-body irradiation in hematopoietic cell transplantation (HCT) preparative reg

179 psychological distress during their child's hematopoietic cell transplantation (HCT) process.

180 prophylaxis after matched-related allogeneic hematopoietic cell transplantation (HCT) recently showed

181 sing polymerase chain reaction in allogeneic hematopoietic cell transplantation (HCT) recipients who

182 ) infection is a significant complication in hematopoietic cell transplantation (HCT) recipients.

183 % of matched, related donor (MRD) allogeneic hematopoietic cell transplantation (HCT) recipients.

184 ersus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients.

185 eria are associated with adverse outcomes in hematopoietic cell transplantation (HCT) recipients.

186 (CMV) is the most common viral infection in hematopoietic cell transplantation (HCT) recipients.

187 Hematopoietic cell transplantation (HCT) remains the onl

188 Allogeneic hematopoietic cell transplantation (HCT) represents a po

189 Allogeneic hematopoietic cell transplantation (HCT) still plays a k

190 e the risks of serious health outcomes among hematopoietic cell transplantation (HCT) survivors versu

191 and functional status in a recent cohort of hematopoietic cell transplantation (HCT) survivors.

192 et al. tackle one of the major obstacles in hematopoietic cell transplantation (HCT) technology: bal

193 trajectory of sexual well-being from before hematopoietic cell transplantation (HCT) to 3 years afte

194 rrent outcomes of unrelated donor allogeneic hematopoietic cell transplantation (HCT) to determine th

195 am infection (BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) utilizing the C

196 nderwent myeloablative HLA-matched unrelated hematopoietic cell transplantation (HCT) were randomly a

197 184 recipients of hematopoietic cell transplantation (HCT) who were at hig

198 uced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) with alemtuzuma

199 matched sibling donors (MSDs) can proceed to hematopoietic cell transplantation (HCT) without conditi

200 mportant to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure th

201 s received total body irradiation (4.5 cGy), hematopoietic cell transplantation (HCT), either marrow

202 etic stem cell (HSC) homing is important for hematopoietic cell transplantation (HCT), especially whe

203 us (PIV) commonly infects patients following hematopoietic cell transplantation (HCT), frequently cau

204 been effective in preventing acute GvHD post hematopoietic cell transplantation (HCT), its efficacy a

205 (GvHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT), mediated prima

206 ce and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT), NK cells deriv

207 rent treatment options, including allogeneic hematopoietic cell transplantation (HCT), often fail to

208 After hematopoietic cell transplantation (HCT), polyoma-BK vir

209 In patients who undergo allogeneic hematopoietic cell transplantation (HCT), post-HCT clone

210 When considering HLA-matched hematopoietic cell transplantation (HCT), sibling and un

211 ith hematologic malignancies cannot tolerate hematopoietic cell transplantation (HCT), whereas others

212 logy) in treatment algorithms for allogeneic hematopoietic cell transplantation (HCT), which implies

213 Both children required allogeneic hematopoietic cell transplantation (HCT), which resolved

214 outcomes in patients who undergo allogeneic hematopoietic cell transplantation (HCT).

215 morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT).

216 tients undergoing cytotoxic chemotherapy and hematopoietic cell transplantation (HCT).

217 metabolism in response to alloantigens after hematopoietic cell transplantation (HCT).

218 ells (Tregs) in a murine model of allogeneic hematopoietic cell transplantation (HCT).

219 ents with hematologic malignancies (HMs) and hematopoietic cell transplantation (HCT).

220 morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT).

221 ed PBMCs obtained 6 mo after unrelated donor hematopoietic cell transplantation (HCT).

222 onditioning for HLA class I or II mismatched hematopoietic cell transplantation (HCT).

223 chimerism and can be induced coincident with hematopoietic cell transplantation (HCT).

224 sease (VOD) can be a difficult problem after hematopoietic cell transplantation (HCT).

225 ctions affect the outcome of unrelated donor hematopoietic cell transplantation (HCT).

226 tor for assessing suitability for allogeneic hematopoietic cell transplantation (HCT).

227 t human erythropoietin (rhEPO) therapy after hematopoietic cell transplantation (HCT).

228 -versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT).

229 ity has a negative impact on the outcomes of hematopoietic cell transplantation (HCT).

230 with symptomatic hemorrhagic cystitis after hematopoietic cell transplantation (HCT).

231 ho receive grafts from female donors (F-->M) hematopoietic cell transplantation (HCT).

232 actory to reinduction, and/or relapsed after hematopoietic cell transplantation (HCT).

233 nd often fatal complication after allogeneic hematopoietic cell transplantation (HCT).

234 of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT).

235 suitable donor are considered for allogeneic hematopoietic cell transplantation (HCT).

236 of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT).

237 morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT).

238 ce of graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT).

239 s-leukemia (GVL) effect is the holy grail of hematopoietic cell transplantation (HCT).

240 -6B) frequently reactivates after allogeneic hematopoietic cell transplantation (HCT).

241 d nonmyeloablative conditioning regimens for hematopoietic cell transplantation (HCT).

242 e (aGVHD) hinders the efficacy of allogeneic hematopoietic cell transplantation (HCT).

243 nked to poor outcomes in patients undergoing hematopoietic cell transplantation (HCT).

244 has had a marked impact on human allogeneic hematopoietic cell transplantation (HCT).

245 ll-recognized after myeloablative allogeneic hematopoietic cell transplantation (HCT).

246 Ss) are life-threatening complications after hematopoietic cell transplantation (HCT).

247 st disease (GVHD) is common after allogeneic hematopoietic cell transplantation (HCT).

248 educed-intensity conditioning, related donor hematopoietic cell transplantation (HCT).

249 , 113 patients with ALL underwent allogeneic hematopoietic cell transplantation (HCT); frequency of S

250 inib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known.

251 ning disease of infants that is curable with hematopoietic cell transplantation if detected early.

252 We compared the outcome of allogeneic hematopoietic cell transplantation in children with acut

253 al donors, and the role of alternative donor hematopoietic cell transplantation in thalassemia is not

254 actions in determining the outcome of murine hematopoietic cell transplantation in vivo.

255 sortium was formed to analyze the results of hematopoietic-cell transplantation in children with seve

256 Allogeneic hematopoietic cell transplantation involves consideratio

257 Although in utero hematopoietic cell transplantation is a promising strate

258 ajor barrier to successful use of allogeneic hematopoietic cell transplantation is acute graft-versus

259 Allogeneic hematopoietic cell transplantation is an established tre

260 Allogeneic hematopoietic cell transplantation is an established tre

261 Hematopoietic cell transplantation is curative in many p

262 Allogeneic hematopoietic cell transplantation is indicated for refr

263 The success of allogeneic hematopoietic cell transplantation is limited by acute g

264 sion acute myeloid leukemia patients receive hematopoietic cell transplantation is referred to as ris

265 t of choice for neutropenia in PIDD, whereas hematopoietic cell transplantation is the only curative

266 Hematopoietic cell transplantation is, to date, the only

267 Evidence supporting the efficacy of in utero hematopoietic cell transplantation (IUHCT) in a valid la

268 In utero hematopoietic cell transplantation (IUHCT) is a novel no

269 major barrier to engraftment after in utero hematopoietic cell transplantation (IUHCT).

270 In utero hematopoietic cell transplantation (IUHCTx) is a promisi

271 sociated with HLA-mismatched unrelated donor hematopoietic cell transplantation limit its general app

272 therapy given in preparation for allogeneic hematopoietic cell transplantation may prime donor T cel

273 ency, early and late complications following hematopoietic cell transplantation might be more promine

274 nd host-versus-graft reactions in the canine hematopoietic cell transplantation model.

275 cute myeloid leukemia patients proceeding to hematopoietic cell transplantation, now the most common

276 supporting the use of alternative donors for hematopoietic cell transplantation of patients with high

277 re previously treated with either autologous hematopoietic cell transplantation or two or more prior

278 analysis of a nonhematologic neoplasm, after hematopoietic cell transplantation, or as a result of ge

279 Autologous hematopoietic cell transplantation, or autotransplantati

280 nt opportunistic pathogen in solid organ and hematopoietic cell transplantation, particularly in lung

281 utcome of 2687 myeloablative unrelated donor hematopoietic cell transplantations performed for malign

282 ptions for relapsed lymphoma post-allogeneic hematopoietic cell transplantation (post-allo-HCT) and t

283 d improved survival in a model of allogeneic hematopoietic cell transplantation, providing the ration

284 ting equations (that adjusted for diagnosis, hematopoietic cell transplantation, race/ethnicity, and

285 ctively, and those from 140 URI samples from hematopoietic cell transplantation recipients were 88% a

286 sociated with higher mortality in allogeneic hematopoietic cell transplantation recipients with LRTD.

287 ntaining at least 100 patients who underwent hematopoietic cell transplantation reporting skin cancer

288 Recently, the Hematopoietic Cell Transplantation-Specific Comorbidity

289 when hosts are sublethally irradiated before hematopoietic cell transplantation, stable and long-term

290 Hematopoietic cell transplantation survivors and sibling

291 daptive immune response caused by allogeneic hematopoietic cell transplantation that have been activa

292 cGVHD) is a major complication of allogeneic hematopoietic cell transplantation that is associated wi

293 t disease (GvHD) is a common complication of hematopoietic cell transplantation that negatively impac

294 (GVHD) is a major complication of allogeneic hematopoietic cell transplantation that resembles autoim

295 ansplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with

296 To investigate the role of mast cells in hematopoietic cell transplantation, we assessed graft-ve

297 In this study, recipients of adult donor hematopoietic cell transplantation were assessed to eval

298 LC-chimerism after sex-mismatched allogeneic hematopoietic cell transplantation with nonmyeloablative

299 mide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of p

300 f treatment, compared with 27 patients after hematopoietic cell transplantation without aGVHD (NONE).